Overview

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective: -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal lymph node neck dissections), with which serum calcium will be raised to corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end of the treatment course.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Eli Lilly and Company
Treatments:
Calcitriol
Calcium
Calcium, Dietary
Parathyroid Hormone
Teriparatide